SRTD Biotech raises €31.5M seed for cell-selective mRNA
SRTD Biotech raised an oversubscribed €31.5 million seed led by Mérieux Equity Partners to take its cell-selective mRNA therapies toward an IND filing.
Also see more funding coverage: /funding/
Founded 2019
SRTD Biotech, a Jülich-based RNA therapeutics startup, has raised an oversubscribed €31.5 million seed round led by Mérieux Equity Partners, with NRW.BANK and Boehringer Ingelheim Venture Fund co-leading, to take its cell-selective mRNA therapies through preclinical development toward an IND filing.
Mérieux leads, Boehringer and NRW.BANK co-lead a €31.5 million seed
SRTD Biotech announced the round on 9 November 2026 in a release published by High-Tech Gründerfonds. The €31.5 million seed, announced in euros and described as oversubscribed, is led by Mérieux Equity Partners through its Mérieux Innovation 2 fund. NRW.BANK co-leads through its NRW.Venture EU Tech&Scale fund, set up under an InvestEU partnership, alongside Boehringer Ingelheim Venture Fund.
Get the Weekly brief
The week’s rounds, last calls and events, every Monday.
Lilly Ventures, High-Tech Gründerfonds and Anobis Asset, a family office based in Freiburg, also joined. HTGF had already backed the company’s earlier seed in 2024. CEO Matthias Alder calls this one “one of the largest biotech seed financings in Europe to date”.
The money goes to preclinical development of targeted RNA therapies in oncology, autoimmune disease and fibrosis, with an IND filing as the stated goal. The company has given no timeline for that filing, and no clinical trials are running yet.
Below, I lay out what the company builds, why a flat market makes this check more interesting, and what the investor mix tells us.
An mRNA switch built in Jülich for the liver first
SRTD Biotech was founded in 2019 in Jülich, near Aachen. The release names Dr. Bernd Hoffmann and Dr. Heribert Bohlen as founders and gives no headcount.
Its “seRNA” technology reads RNA disease markers inside a cell and switches on mRNA expression only when those markers are present. The aim is to keep the therapy quiet in healthy tissue. Delivery runs through fusogenic lipid nanoparticles intended to reach the liver and lung, with the brain and other organs also in scope. Behind both sits a synthetic biology platform that uses bioinformatics and AI-driven RNA design. The company’s site names liver cancer as its starting indication.
Imagine if an mRNA drug could pass through the liver and switch on only in tumor cells. That is what SRTD is building toward, and all of it is still preclinical.
The leadership has a dealmaker’s profile. Alder was previously CEO, COO and CBO at listed biotechs in the US and Europe and has led more than $10 billion in biotech transactions. CTO Dr. Heinz Koeppl founded the synthetic biology platform and is a professor at TU Darmstadt, where he directs the Centre for Synthetic Biology. CBO Dr. Jens Hennecke brings more than 25 years in licensing and M&A.
A $7.7 billion mRNA market forecast to stand still
The segment SRTD sells into is forecast flat. BCC Research, in a report published in September 2025, sized the global mRNA therapeutics market at $8.36 billion in 2024, estimated $7.71 billion for 2025 and projects $7.69 billion in 2030, a compound annual growth rate of -0.04 percent over 2025-2030.
A seed this size is a bet on next-generation, cell-selective mRNA. The headline market will lift nobody between now and 2030.
The good news is that capital for European therapeutics moved hard the same week. Our fundraising data logs two rounds announced on 5 November 2026: T-Therapeutics’ $133 million Series B, co-led by Advent Life Sciences and British Business Bank, and Alethio Therapeutics’ €80.3 million Series A with Sofinnova Partners and RA Capital. SRTD’s seed comes to close to 40 percent of Alethio’s Series A, at a stage with no clinical data on the table.
Boehringer and Lilly arrive before the first patient
Two pharma corporate funds, Boehringer Ingelheim Venture Fund and Lilly Ventures, are on a preclinical seed. That is the detail I find most telling. Both are in years before an IND filing exists.
Kristin Thompson, Director at Mérieux Equity Partners, put the lead’s view plainly: “We believe SRTD Biotech has the potential to redefine what is possible with mRNA therapeutics.” Public money adds a regional thread. NRW.BANK’s check comes through an InvestEU partnership, and Johanna Antonie Tjaden-Schulte, Managing Board Member at NRW.BANK, framed it around home turf, saying research from North Rhine-Westphalia “can open up new ways to treat many diseases”.
We Europeans like to complain that our seed rounds are too small to build a drug company on. This one answers that complaint, and the founders still have years of preclinical work ahead. The fact remains that a large seed buys time in the lab and guarantees nothing in the clinic.
How many of Europe’s next RNA spinouts will need a seed this size to reach their first patient?
The IND filing is the next date to watch
SRTD has named an IND filing as its next milestone, with no date attached. Until then, the public signals to track are which indication follows liver cancer, whether the delivery system reaches the lung and brain as intended, and whether the pharma funds on this round return for the next one.
Keep an eye on Jülich, and let’s build more European RNA companies with this kind of runway!
